1. Home
  2. UCL vs ALXO Comparison

UCL vs ALXO Comparison

Compare UCL & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo uCloudlink Group Inc.

UCL

uCloudlink Group Inc.

N/A

Current Price

$1.78

Market Cap

74.5M

ML Signal

N/A

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$1.14

Market Cap

68.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UCL
ALXO
Founded
2014
2015
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.5M
68.3M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
UCL
ALXO
Price
$1.78
$1.14
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$3.30
AVG Volume (30 Days)
19.7K
178.7K
Earning Date
11-12-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
8.06
N/A
EPS
0.12
N/A
Revenue
$85,239,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$20.86
N/A
P/E Ratio
$13.47
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$0.40
52 Week High
$4.19
$2.27

Technical Indicators

Market Signals
Indicator
UCL
ALXO
Relative Strength Index (RSI) 38.52 34.67
Support Level $1.60 $1.37
Resistance Level $2.25 $1.53
Average True Range (ATR) 0.17 0.09
MACD -0.02 -0.03
Stochastic Oscillator 10.26 2.33

Price Performance

Historical Comparison
UCL
ALXO

About UCL uCloudlink Group Inc.

Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: